Orion Oyj stock (FI0009014377): Dividend proposal and earnings call in focus

Orion Oyj has proposed a 2025 dividend of EUR 1.80 per share and is scheduled to hold its 2025 earnings call on February 12, 2026, drawing attention from investors.

Orion Oyj has proposed a dividend of EUR 1.80 per share for the 2025 financial year, a move that underpins its commitment to returning capital to shareholders while maintaining its pharmaceutical growth strategy, according to a company announcement compiled in analyst consensus data as of February 12, 2026.Marketscreener consensus as of 02/12/2026

The Finnish pharmaceutical group also scheduled its 2025 earnings call for February 12, 2026, providing investors with an opportunity to review full?year results, discuss outlook, and assess management’s commentary on key markets and product pipelines.Marketscreener consensus as of 02/12/2026

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Orion Oyj
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Finland
• Core markets: Finland, Scandinavia, rest of Europe, North America, and other international markets
• Key revenue drivers: Human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs)
• Home exchange/listing venue: Nasdaq Helsinki (ticker: ORNBV)
• Trading currency: EUR

Orion Oyj: core business model

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals as well as active pharmaceutical ingredients (APIs), serving patients and animal?health customers across Finland, Scandinavia, the rest of Europe, North America, and other international markets.Simply Wall St profile as of 05/09/2026

The company combines proprietary research and development with contract manufacturing and marketing partnerships, allowing it to participate in both branded prescription products and generic or API?supply segments.Simply Wall St profile as of 05/09/2026

This diversified model helps Orion balance exposure to patent?driven growth in innovative medicines with more stable, volume?based revenue streams from generics and APIs.Simply Wall St profile as of 05/09/2026

Main revenue and product drivers for Orion Oyj

Orion’s main revenue drivers include proprietary human pharmaceuticals in therapeutic areas such as pain, oncology, and central nervous system disorders, as well as veterinary medicines and contract manufacturing of APIs for other pharmaceutical companies.Simply Wall St profile as of 05/09/2026

The group’s international footprint, particularly in Europe and North America, supports recurring sales of established products while providing a platform for launching new indications and formulations.Simply Wall St profile as of 05/09/2026

Recent analyst commentary notes that Orion has delivered solid returns over the past year, reflecting both underlying business performance and investor interest in its dividend?paying profile.Simply Wall St article as of 05/09/2026

Conclusion

Orion Oyj continues to position itself as a dividend?paying pharmaceutical player with a diversified portfolio of human and veterinary medicines and APIs across multiple regions.Simply Wall St profile as of 05/09/2026

The proposed 2025 dividend of EUR 1.80 per share and the scheduled 2025 earnings call on February 12, 2026, provide focal points for investors assessing the company’s financial discipline and growth trajectory.Marketscreener consensus as of 02/12/2026

For US?based investors, Orion offers exposure to a European pharmaceutical manufacturer with international operations, though the stock trades in euros on Nasdaq Helsinki and is subject to currency and regional market risks.Simply Wall St profile as of 05/09/2026

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.